Company Description
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extract...
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.
Valuation
Price to Sales Ratio
4.95
Price to Book Ratio
3.50
Enterprise Value to Sales
5.67
Total Debt to Enterprise Value
0.29
Efficiency
Revenue/Employee
204,351.00
Income Per Employee
-263,178.00
Receivables Turnover
5.00
Total Asset Turnover
0.23
Liquidity
Current Ratio
1.91
Quick Ratio
1.40
Cash Ratio
1.05
Profitability
Gross Margin
5.45
Operating Margin
-60.49
Pretax Margin
-128.61
Net Margin
-128.79
Return on Assets
-29.43
Return on Equity
-82.25
Return on Total Capital
-17.33
Return on Invested Capital
-37.10
Capital Structure
Total Debt to Total Equity
91.28
Total Debt to Total Capital
47.72
Total Debt to Total Assets
36.08
Long-Term Debt to Equity
90.10
Long-Term Debt to Total Capital
47.10
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Brendan Kennedy | 47 | 2018 | President, Chief Executive Officer & Director |
Mr. Jon Levin | 50 | 2020 | Chief Operating Officer |
Mr. Michael Kruteck | 57 | 2020 | Chief Financial Officer |
Dr. Joshua Eades | - | 2014 | Chief Science Officer & Vice President |
Mr. Michael Auerbach | 42 | - | Director |
Insider Actions
04/01/2021 |
Michael B. Shtender-Auerbach Director |
2,188 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/18/2021 |
Andrew Pucher Chief Corporate Dev Officer |
3,495 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/18/2021 |
Andrew Pucher Chief Corporate Dev Officer |
7,497 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/16/2021 |
Michael B. Shtender-Auerbach Director |
31,164 | 0 | |
03/16/2021 |
Michael B. Shtender-Auerbach Director |
73,593 | 0 | |
03/16/2021 |
Michael B. Shtender-Auerbach Director |
268,095 | 0 | |
03/16/2021 |
Michael B. Shtender-Auerbach Director |
685,424 | 0 | |
03/05/2021 |
Michael Kruteck Chief Financial Officer |
14,646 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/05/2021 |
Jon Levin Chief Operating Officer |
15,830 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/05/2021 |
Michael Kruteck Chief Financial Officer |
33,360 | Award at $0 per share. | 0 |
03/05/2021 |
Jon Levin Chief Operating Officer |
33,360 | Award at $0 per share. | 0 |
03/01/2021 |
Rebekah Dopp Director |
2,187 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/01/2021 |
Christine Thompson St. Clare Director |
2,187 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/23/2021 |
Michael B. Shtender-Auerbach Director |
5,929 | 0 | |
02/23/2021 |
Michael B. Shtender-Auerbach Director |
20,392 | 0 | |
02/23/2021 |
Michael B. Shtender-Auerbach Director |
89,349 | 0 | |
02/23/2021 |
Michael B. Shtender-Auerbach Director |
228,433 | 0 | |
02/19/2021 |
Michael Kruteck Chief Financial Officer |
23,476 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/19/2021 |
Jon Levin Chief Operating Officer |
26,982 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/19/2021 |
Michael Kruteck Chief Financial Officer |
53,191 | Award at $0 per share. | 0 |
02/19/2021 |
Jon Levin Chief Operating Officer |
56,738 | Award at $0 per share. | 0 |
01/25/2021 |
Brendan Kennedy President and CEO; Director |
57 | 0 | |
01/25/2021 |
Brendan Kennedy President and CEO; Director |
3,371 | 0 | |
01/25/2021 |
Michael B. Shtender-Auerbach Director |
202 | 0 | |
01/25/2021 |
Michael B. Shtender-Auerbach Director |
517 | 0 | |
01/25/2021 |
Michael B. Shtender-Auerbach Director |
116 | 0 | |
01/01/2021 |
Brendan Kennedy President and CEO; Director |
12,777 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2021 |
Brendan Kennedy President and CEO; Director |
46,875 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/01/2021 |
Michael B. Shtender-Auerbach Director |
2,187 | Derivative/Non-derivative trans. at $0 per share. | 0 |
12/18/2020 |
Michael B. Shtender-Auerbach Director |
3,595 | 0 | |
12/18/2020 |
Michael B. Shtender-Auerbach Director |
13,895 | 0 | |
12/18/2020 |
Andrew Pucher Chief Corporate Dev Officer |
7,497 | Derivative/Non-derivative trans. at $0 per share. | 0 |
12/18/2020 |
Michael B. Shtender-Auerbach Director |
61,289 | 0 | |
12/18/2020 |
Michael B. Shtender-Auerbach Director |
156,693 | 0 | |
12/18/2020 |
Andrew Pucher Chief Corporate Dev Officer |
3,303 | Derivative/Non-derivative trans. at $0 per share. | 0 |
MarketWatch News on TLRY
-
Marijuana Stock Aphria Tanks After Net Loss Widens
- Connor Smith
-
Pot Producer Green Thumb Reports Strong Earnings
- Bill Alpert
-
Why Curaleaf Is Upbeat About Cannabis Reform
- Bill Alpert
-
Pot or Alcohol, Barron’s Has Never Favored Prohibition
- Kenneth G. Pringle
-
Tilray stock price target raised to $21.00 from $9.20 at Stifel Nicolaus
- Tomi Kilgore
-
Marijuana Stock Tilray Is Rising. A Bull Is Stepping Aside.
- Connor Smith
-
Walmart Drops, Tilray Pops, and Tech Is Leading the Market Lower Again
- Jacob Sonenshine
- Loading more headlines...
Other News on TLRY
-
Aphria Gets Smoked On Surprisingly Awful Earnings
- InvestorPlace.com
-
Aphria Investors Are Just Waiting On the Votes to Be Counted
- InvestorPlace.com
-
OGI, TLRY, APHA among premarket losers
- Seeking Alpha
-
Why Marijuana Stocks Went to Pot Monday
- Motley Fool
-
Cannabis Stocks: Why GRWG, SNDL, CGC, TLRY, APHA Stocks Are Getting Smoked
- InvestorPlace.com
-
Here's Why Investors Hated Aphria's Q3 Results
- Motley Fool
-
Why Aphria and Tilray Stocks Are Tanking Today
- Motley Fool
-
The Aphria Merger Will Change Everything For Tilray
- InvestorPlace.com
-
APHA Stock: The Big Covid-19 Toll Sending Aphria Stumbling Today
- InvestorPlace.com
-
ICICI Bank, Tata Motors among premarket losers' pack
- Seeking Alpha
-
Wall Street Breakfast: Alibaba Relief
- Seeking Alpha
-
Tilray Bulls Should Chill and Root for Pullbacks Ahead Of Aphria Merger
- InvestorPlace.com
-
Wall Street Breakfast: The Week Ahead
- Seeking Alpha
-
- Seeking Alpha
- Loading more headlines...